As of 2025-10-23, the Intrinsic Value of Nirvana Life Sciences Inc (NIRV.CN) is -1.73 CAD. This NIRV.CN valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.14 CAD, the upside of Nirvana Life Sciences Inc is -1,336.79%.
Based on its market price of 0.14 CAD and our intrinsic valuation, Nirvana Life Sciences Inc (NIRV.CN) is overvalued by 1,336.79%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -1.73 - -1.73 | -1.73 | -1,336.79% |
| DDM - Stable | (1.10) - (1.99) | (1.54) | -1203.4% |
| DDM - Multi | (0.81) - (1.18) | (0.96) | -787.6% |
| Market Cap (mil) | 0.14 |
| Beta | -3.58 |
| Outstanding shares (mil) | 1.00 |
| Enterprise Value (mil) | 0.24 |
| Market risk premium | 5.10% |
| Cost of Equity | 22.86% |
| Cost of Debt | 5.00% |
| WACC | 14.94% |